QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:KALV

KalVista Pharmaceuticals Stock Forecast, Price & News

$16.44
+0.31 (+1.92 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.79
Now: $16.44
$16.61
50-Day Range
$15.64
MA: $17.57
$19.28
52-Week Range
$5.61
Now: $16.44
$20.21
Volume45,990 shs
Average Volume129,219 shs
Market Capitalization$294.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
KalVista Pharmaceuticals logo

MarketRank

Overall MarketRank

1.95 out of 5 stars

Medical Sector

68th out of 1,922 stocks

Pharmaceutical Preparations Industry

27th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075
Employees56
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.69 million
Book Value$4.69 per share

Profitability

Net Income$-29,120,000.00
Net Margins-229.45%

Miscellaneous

Market Cap$294.97 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable
$16.44
+0.31 (+1.92 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has KalVista Pharmaceuticals' stock been impacted by COVID-19?

KalVista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KALV shares have increased by 85.6% and is now trading at $16.44.
View which stocks have been most impacted by COVID-19
.

Is KalVista Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KalVista Pharmaceuticals stock.
View analyst ratings for KalVista Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than KalVista Pharmaceuticals?

Wall Street analysts have given KalVista Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but KalVista Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is KalVista Pharmaceuticals' next earnings date?

KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for KalVista Pharmaceuticals
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Wednesday, December, 9th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.09. KalVista Pharmaceuticals had a negative trailing twelve-month return on equity of 47.45% and a negative net margin of 229.45%.
View KalVista Pharmaceuticals' earnings history
.

What price target have analysts set for KALV?

3 brokers have issued 1 year target prices for KalVista Pharmaceuticals' stock. Their forecasts range from $25.00 to $39.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 90.6% from the stock's current price.
View analysts' price targets for KalVista Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of KalVista Pharmaceuticals' key competitors?

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 46, Pay $568k)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 55, Pay $446.9k)
  • Mr. Christopher M. Yea Ph.D., Chief Devel. Officer (Age 57, Pay $445.27k)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 61)
  • Leah Monteiro, Director of Corp. Communications & Investor Relations
  • Ms. Rachel Morten, Head of Regulatory Affairs and QA
  • Mr. Andreas Maetzel, Sr. VP of Medical (Age 58)
  • Mr. Michael D. Smith Pharm.D., Sr. VP of Devel. (Age 42)
  • Mr. Stephen Donnelly, Director of Fin. and Company Sec.
  • Mr. John B. McKune, VP of Fin. (Age 45)

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $16.44.

How big of a company is KalVista Pharmaceuticals?

KalVista Pharmaceuticals has a market capitalization of $294.97 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. KalVista Pharmaceuticals employs 56 workers across the globe.

What is KalVista Pharmaceuticals' official website?

The official website for KalVista Pharmaceuticals is www.kalvista.com.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.